Noxopharm (ASX:NOX) Treasury Stock : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Noxopharm's treasury stock for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Noxopharm Treasury Stock Historical Data

The historical data trend for Noxopharm's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Treasury Stock Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Treasury Stock

Get a 7-Day Free Trial

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Treasury Stock	Get a 7-Day Free Trial											-	-	-	-	-

Noxopharm Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Noxopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm Headlines

No Headlines